Tuberculosis vaccine trials

The Lancet

Volumn 381, Issue 9885, 2013, Pages 2252-2253

  Behr, Marcel A ^a   Schwartzman, Kevin ^a   Pai, Madhukar ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; GAMMA INTERFERON; PLACEBO;

CLINICAL TRIAL (TOPIC); HEALTH CARE PERSONNEL; INTERFERON GAMMA RELEASE ASSAY; LETTER; PRIORITY JOURNAL; REPRODUCIBILITY; TUBERCULOSIS;

EID: 84879494970     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)61481-6     Document Type: Letter

References (5)

1. Tameris M, Hatherill M, Landry B, et al. Safety and effi cacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 2013; 381: 1021-28.
2. Pai M. Serial testing with TB interferongamma release assays: toward a nuanced understanding. Chest 2012; 142: 1366-67.
3. Zwerling A, van den Hof S, Scholten J, Cobelens F, Menzies D, Pai M. Interferon-gamma release assays for tuberculosis screening of healthcare workers: a systematic review. Thorax 2012; 67: 62-70.
4. Metcalfe JZ, Cattamanchi A, McCulloch CE, Lew JD, Ha NP, Graviss EA. Test Variability of the QuantiFERON-TB Gold In-Tube Assay in Clinical Practice. Am J Respir Crit Care Med 2013; 187: 206-11.
5. Zwerling A, Benedetti A, Cojocariu M, et al. Repeat IGRA testing in Canadian health workers: conversions or unexplained variability? PLoS One 2013; 8: e54748.